| Popis: |
Introduction: COVID-19, caused by SARS-CoV-2 or novel corona virus is declared as a global emergency. Researchers are working hard to develop effective remedy and vaccine, but still the challenge to manage the spread and disease progression is existing. In Ayurveda, a good number of herbs are ascribed for health promotion and longevity; many of them are scientifically proven to boost immunity. Jeevaneeya mahakashaya of Charaka Samhita is such group of ten herbs enumerated for longevity and rejuvenation. However, few of the herbs of Jeevaneeya mahakashaya are endangered and not available easily. Thus, in the present article, the herbs of Jeevaneeya mahakashaya having Pratinidhi (substitutes) suggested in Bhavaprakasha Nighantu were reviewed. Objective: The objective of this study is to analyze the rationality and applicability of Jeevaneeya mahakashaya in the prevention and management of COVID-19. Data Source: The data was collected from Charaka Samhita and Bhavaprakasha Nighantu and PubMed database. Review Methods: Jeevaneeya mahakashaya and its Pratinidhi herbs were reviewed from Charaka Samhita and Bhavaprakasha Nighantu, respectively. Herbs of Jeevaneeya mahakashaya were also reviewed from PubMed data base for reported pharmacological activities beneficial in the management of COVID-19 by their botanical name. Results: The literature search revealed that the herbs enumerated in the Jeevaneeya mahakashaya were scientifically evaluated in various preclinical and clinical studies and showed anti-viral, anti-bacterial, immunomodulatory, anti-inflammatory, anti-oxidant, anti-tussive, cardio-protective, neuroprotective, nephroprotective, and hepatoprotective activity. These potential of herbs may help in CD4+ and CD8+ cell proliferation, interleukin 6, tumour necrosis factor alpha, inflammatory markers inhibition. It also protects various organs from damage, and improves respiration. Conclusion: The rational use of plants of Jeevaneeya mahakashaya may help in the prevention and management of SARS-CoV 2. |
